miRNA: a promising therapeutic target in cancer
microRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by
complementarity pairing. Since discovery, they have been reported to be involved in a …
complementarity pairing. Since discovery, they have been reported to be involved in a …
Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update
Since the discovery of the first microRNAs (miRNAs, miRs), the understanding of miRNA
biology has expanded substantially. miRNAs are involved and described as master …
biology has expanded substantially. miRNAs are involved and described as master …
[HTML][HTML] Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers
L Zhang, B Ye, Z Chen, ZS Chen - Acta Pharmaceutica Sinica B, 2023 - Elsevier
Chemotherapy is one of the important methods to treat cancer, and the emergence of
multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy …
multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy …
ROS and miRNA dysregulation in ovarian cancer development, angiogenesis and therapeutic resistance
DC Stieg, Y Wang, LZ Liu, BH Jiang - International Journal of Molecular …, 2022 - mdpi.com
The diverse repertoires of cellular mechanisms that progress certain cancer types are being
uncovered by recent research and leading to more effective treatment options. Ovarian …
uncovered by recent research and leading to more effective treatment options. Ovarian …
[HTML][HTML] MiR-223-3p in cancer development and cancer drug resistance: same coin, different faces
MicroRNAs (miRNAs) are mighty post-transcriptional regulators in cell physiology and
pathophysiology. In this review, we focus on the role of miR-223-3p (henceforth miR-223) in …
pathophysiology. In this review, we focus on the role of miR-223-3p (henceforth miR-223) in …
Development and perspectives: multifunctional nucleic acid nanomedicines for treatment of gynecological cancers
Gynecological malignancies are a significant cause of morbidity and mortality across the
globe. Due to delayed presentation, gynecological cancer patients are often referred late in …
globe. Due to delayed presentation, gynecological cancer patients are often referred late in …
Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance
miRNA are critical messengers in the tumor microenvironment (TME) that influence various
processes leading to immune suppression, tumor progression, metastasis and resistance …
processes leading to immune suppression, tumor progression, metastasis and resistance …
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
A Moniot, C Schneider, L Chardin, E Yaniz-Galende… - Molecular Cancer, 2024 - Springer
Background Ovarian cancer (OC) remains one of the most challenging and deadly
malignancies facing women today. While PARP inhibitors (PARPis) have transformed the …
malignancies facing women today. While PARP inhibitors (PARPis) have transformed the …
Engineering of inhalable nano-in-microparticles for co-delivery of small molecules and miRNAs
M Motiei, O Mišík, TH Truong, F Lizal, P Humpolíček… - Discover Nano, 2023 - Springer
In this study, novel Trojan particles were engineered for direct delivery of doxorubicin (DOX)
and miR-34a as model drugs to the lungs to raise local drug concentration, decrease …
and miR-34a as model drugs to the lungs to raise local drug concentration, decrease …
Transcriptome profiling and characterization of peritoneal metastasis ovarian cancer xenografts in humanized mice
SW Kang, J Lee, OJ Kang, YM Kim, EK Choi… - Scientific Reports, 2024 - nature.com
Although immunotherapy has not yet been as successful in ovarian cancer (OC), it remains
a potential therapeutic strategy. Preclinical models of OC are necessary to evaluate the …
a potential therapeutic strategy. Preclinical models of OC are necessary to evaluate the …